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isamide/levetiracetam,	 or	 mitochondrial	 supplements?	 (b)	 Should	 the	 following	
pharmacologic	agents	be	used	for	abortive	treatment:	triptans	or	aprepitant?
Results: We	 found	 very	 low‐quality	 evidence	 to	 support	 the	 use	 of	 the	 following	
agents	 for	 prophylactic	 and	 abortive	 treatment	 of	 CVS:	 amitriptyline,	 topiramate,	
aprepitant,	 zonisamide/levetiracetam,	 and	 mitochondrial	 supplements.	 We	 have	
moderate	certainty	of	evidence	for	the	use	of	triptans	as	abortive	therapy.	We	found	
limited	evidence	to	support	the	use	of	ondansetron	and	the	treatment	of	co‐morbid	
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1  | INTRODUC TION
Cyclic	 vomiting	 syndrome	 (CVS)	 is	 a	 chronic,	 debilitating	 illness	
that	is	characterized	by	recurrent	episodes	of	intense	nausea	and	
vomiting.	 Although	 the	 true	 prevalence	 of	 CVS	 in	 adults	 in	 the	
general	population	 remains	uncertain,	 it	 is	not	a	 rare	disorder.	A	
recent	population‐based	study	noted	that	the	US	prevalence	was	
2%	 among	 adults,	 mirroring	 prevalence	 estimates	 in	 children.1 
Another	estimated	that	~10%	of	outpatients	presenting	to	a	ter‐
tiary	 gastroenterology	 clinic	met	 the	Rome	 III	 criteria	 for	 the	 ill‐
ness;2	however,	even	 in	 this	clinical	setting,	CVS	was	considered	
as	a	potential	diagnosis	in	only	a	small	minority	of	these	patients.	
This	 finding	 highlights	 the	 poor	 recognition	 of	 CVS	 in	 adults	 by	
clinicians,	 with	 many	 patients	 continuing	 to	 suffer	 for	 several	





This	 evidence	 review	 represents	 a	 foundational	 effort	 by	 the	
American	Neurogastroenterology	 and	Motility	 Society	 (ANMS)	 and	
the	Cyclic	Vomiting	Syndrome	Association	(CVSA)	to	develop	recom‐
mendations	based	on	the	Grading	of	Recommendations	Assessment,	
Development,	 and	Evaluation	 (GRADE)	 framework	 to	provide	a	 ro‐





selected	 by	 the	CVS	 guideline	 committee	 task	 chair	 (T.V.),	 co‐chair	
(B.L.),	and	former	ANMS	council	member	(B.M.)	and	the	CVSA	based	
on	 their	 clinical	 and	methodological	 expertise.	All	 members	 of	 the	




This	 evidence	 review	was	 developed	 using	 the	 GRADE	 framework	
to	 develop	 clinically	 focused	 questions,	 and	 identify,	 synthesize,	
and	 evaluate	 the	 quality	 of	 the	 supporting	 evidence	 to	 inform	 a	
recommendation.3
2.2 | Formulation of clinical questions




outcomes (O) (Table 1). The population	was	adult	patients	with	CVS.	
The intervention	was	one	of	numerous	therapies	used	in	CVS.	The	pre‐









all outcomes would not be available in the published literature.
2.4 | Systematic review process
2.4.1 | Search strategy
The	 literature	search	was	performed	 initially	 in	June	2016	and	up‐





















     |  3 of 29SHARAF et Al.
Details	of	the	search	strategy	are	reported	in	the	Online	Supplement.	
Individual	studies	were	identified	via	searches	of	three	bibliographic	
databases: PubMed	 (includes	MEDLINE),	SCOPUS	 (a	 large,	multidis‐
ciplinary	 database),	 and	CINAHL	(the	 Cumulative	 Index	 to	 Nursing	
and	 Allied	 Health	 Literature).	 Given	 the	 acknowledged	 possibility	
of	diagnostic	misclassification,	 individual	search	strategies	 included	
the	following	terms:	cyclic vomiting; cyclical vomiting; cannabinoid hy‐
peremesis; functional vomiting; abdominal migraine; and periodic syn‐
drome.	The	searches	excluded	animal‐only	studies	and	non–English	




For	all	PICOs,	 the	a	priori	 intent	was	 to	 rely	upon	high‐quality	





observational studies and observational studies were then consid‐
ered	to	inform	the	evidence.	Case	series	of	fewer	than	10	individuals	
were	excluded,	as	were	narrative	reviews.
TA B L E  1  PICO	questions
PICO questions






3. Zonisamide  
Levetiracetam	
4.	Aprepitant	

































F I G U R E  1  PRISMA	flow	diagram















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Reviews	 and	 Meta‐analyses	 (PRISMA)	 guidelines	 to	 develop	 the	
review.	A	PRISMA	flow	diagram	is	 included	 in	Figure	1.	The	titles/
abstracts	from	the	database	searches	were	uploaded	to	Covidence	
(http://covidence.org),	 a	 Web‐based	 application	 that	 facilitates	
screening	 and	 reviewing	 studies	 for	 systematic	 reviews.	 All	 titles	
and abstracts were screened by two researchers (R.S. and S.S.) with 
disagreements	regarding	inclusion	and	exclusion	resolved	by	discus‐









Given	 the	 size	 and	heterogeneity	of	 included	 studies,	 the	majority	of	
results were suitable to narrative summary. Quantitative outcomes were 
calculated using Open Meta (http://www.cebm.brown.edu/openmeta/).
2.6 | Quality or certainty of evidence
The	GRADE	approach	was	used	to	rate	the	certainty	in	the	evidence.	
In	this	approach,	direct	evidence	from	RCTs	starts	at	high	quality	and	
can	be	rated	down	to	 levels	of	moderate,	 low,	and	very	 low	quality,	
based	on	risk	of	bias	in	the	body	of	evidence	(or	study	quality),	 indi‐
rectness	 (addressing	a	different	but	related	population,	 intervention,	



















and any disagreements were resolved by group consensus.











quality observational studies leaving us with low‐ or very low‐quality cer‐
tainty	in	the	evidence	across	outcomes.	Given	the	paucity	of	literature	on	
the	topic,	studies	of	all	populations	 (adult	and	pediatric)	were	 included	







3.2.1 | Should tricyclic antidepressants (TCAs) be 









triptyline's	 symptomatic	effect.	A	summary	estimate	 from	all	 included	
data	revealed	that	approximately	70%	of	patients	with	CVS	exhibited	a	
symptom	response	(variably	defined	for	variable	durations).	Six	studies	











est patient cohorts and noted that 72/139 pediatric patients and 39/54 
(72%)	adults	experienced	TCA‐related	side	effects	and	29/137	pediatric	
patients and 13/61 (21%) adult patients discontinued amitriptyline be‐
cause	of	 side	effects.7	However,	 adverse	events	 leading	 to	 treatment	






regarding	 inconsistency,	 indirectness	 (many	 of	 the	 studies	 included	
only	pediatric	patients),	and	imprecision	(for	a	few	of	the	outcomes).
3.2.2 | Should topiramate be used as 
prophylactic therapy in adults with CVS?
Key message







(compared	 to	 the	 propranolol	 group)	 had	 significantly	 fewer	 epi‐
sodes	of	vomiting/cycle	before	treatment,	fewer	attacks/year	after	
treatment,	 decreased	 median	 duration	 of	 cycles,	 and	 fewer	 peak	
number	of	emeses/hour	during	an	attack.	As	such,	patients	 in	 the	
topiramate group might have been less severe prior to treatment 
than	 the	 propranolol	 group.	 Patients	were	 followed	 for	 1	year.	 At	
follow‐up,	responder	rates	(patients	who	had	zero	attacks	in	the	year	




in	number	of	episodes.	Per	 the	study,	 the	 four	patients	who	were	
non‐responsive	to	propranolol	were	treated	with	topiramate,	and	all	
of	 them	had	a	 “satisfactory	 response,”	 though	this	was	not	clearly	
defined	by	 the	 authors.	 The	one	patient	who	was	non‐responsive	
to	topiramate	was	also	non‐responsive	to	other	medications,	includ‐
ing	propranolol,	 amitriptyline,	and	cyproheptadine.	One	additional	
study reported on topiramate use in adults (Kumar et al.); in this 
study,	18/92	adults	were	treated	with	topiramate,	but	not	enough	
detail	was	provided	to	discern	the	efficacy	of	topiramate	alone,	as	




events between the propranolol and topiramate groups.15 Two 
patients	 experienced	 drowsiness	 and	 dizziness	 with	 topiramate,	
and	mean	weight	loss	after	the	end	of	12	months	was	1.1	±	0.5	kg	
(2.9%).



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































     |  21 of 29SHARAF et Al.
Certainty in effects
The	overall	 certainty	 in	 the	effects	was	very	 low	due	 to	concerns	
about	study	quality,	imprecision	(few	events	and	small	sample	size),	
and indirectness (the study population was pediatric patients)
3.2.3 | Should aprepitant be used as 







abortive therapy and	 as	prophylactic	 therapy	 in	CVS.16 This study 
by	 Cristofori	 et	al.,	 published	 in	 2014,	 included	 pediatric	 patients	
and	was	retrospective	in	design,	collecting	data	from	administrative,	
pharmacy,	 and	 clinical	 databases	 as	 well	 as	 telephone	 interviews	
with	parents	of	patients.	The	41	included	patients	met	NASPGHAN	
criteria	 for	 diagnosis	 of	 CVS	 and	 had	 failed	 or	 could	 not	 tolerate	
past	 treatments	 (Table	2a,b).	 Forty‐one	 children	 and	 adolescents	









tial	 response	 (≥50%	 reduction	 in	 both	 frequency	 and	 intensity	 of	
CVS	symptoms),	no	response	(<50%	reduction	in	CVS	frequency	and	
intensity),	CVS	episodes/year,	hospital	admissions/year,	duration	of	




In	 the	prophylactic	group,	at	12‐month	 follow‐up,	19%	of	 in‐




With	 respect	 to	 adverse	events,	 in	 the	prophylaxis	 group,	one	
patient	 discontinued	 therapy	 due	 to	 severe	 migraine	 (1/16,	 6%).	
Other	 side	 effects	 noted	 included	 hiccups	 (3/16,	 19%),	 asthenia/






the	 study	 included	 a	 population	 that	 failed	 prior	 CVS	 treatments,	
and was on several concomitant medications. Some adolescents 
were	at	an	adult	weight	(>60	kg)	in	the	prophylactic	group	and	were	
dosed	accordingly,	making	this	less	of	a	concern.
3.2.4 | Should zonisamide or levetiracetam be used 






One retrospective study met inclusion criteria.17	 Clouse	 et	al.	 re‐
viewed	outpatient	records	and	conducted	interviews	of	20	adult	pa‐
tients	with	CVS	who	had	 received	prophylactic	 zonisamide	 (median	





Outcomes	measured	 included	 episode	 frequency	 and	 change	 in	
symptoms.	A	score	≥	2	was	required	for	a	“favorable”	clinical	response.	
“Better”	 as	 a	 clinical	 response	was	not	defined.	The	 study	used	 the	
following	 Likert	 scale:	 0	=	no	 significant	 improvement	 or	 worse;	















levetiracetam	 (3000	mg/day).	 Five	 subjects	 out	 of	 20	 reported	
depression,	muscle	weakness,	difficulty	 sleeping,	dizziness,	poor	
concentration/memory,	 confusion,	 or	 tiredness/fatigue.	 One	
subject	on	 levetiracetam	developed	angioedema,	which	resolved	
when	 switched	 to	 zonisamide.	 Only	 one	 subject	 out	 of	 20	 re‐
ported	antiepileptic	drugs	 intolerable	 in	spite	of	switching	drugs	
and dosages.

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































24 of 29  |     SHARAF et Al.
3.2.5 | Should mitochondrial supplements be used 
as prophylactic therapy in adults with CVS?
Key message




The	only	 comparative	 study	 to	 evaluate	 the	 efficacy	 of	Coenzyme	
Q10	was	conducted	by	Boles	et	al.	(2010).7	In	this	study,	the	authors	
compared	the	efficacy	of	Coenzyme	Q10	to	amitriptyline	in	patients	









study	 included	 riboflavin	but	did	not	 report	on	 response	 for	 these	
patients.
The	majority	of	 studies	 that	 reported	on	 the	use	of	mitochon‐




Data	on	 the	 reported	prevalence	of	mitochondrial	 supplement	
therapy	 as	 co‐interventions	 are	 reviewed	 below.	 The	 Lee	 et	al.	
(2012)	systematic	review	was	not	used	to	inform	this	outcome	be‐
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The certainty in the evidence was deemed to be very low due to 





3.3.1 | Should triptans be used as abortive therapy 
in adults with CVS?
Key message
There	is	moderate	certainty	in	the	evidence	for	the	use	of	triptans	
as	 abortive	 therapy	 in	 CVS,	 primarily	 based	 on	 indirect	 data.	 See	
Table	8	for	full	evidence	profile.
Potential benefits/harms
We	 identified	 four	 studies	 that	met	 inclusion	 criteria	 and	 that	 re‐
ported	 on	 the	 use	 of	 triptans	 as	 abortive	 therapy	 in	 CVS.	 One	






Rome	 III	 criteria	 for	 CVS.12 Data were collected on 101 patients 




a	 prospective	 cohort	 study	 that	 took	 place	 at	 Teikyo	 University	
Hospital	in	Japan.21	Patients	had	been	diagnosed	with	severe	CVS	
by	 a	 pediatric	 neurologist	 per	 the	 International	 Classification	 of	
Headache	Disorders.	Patients	were	given	sumatriptan,	as	either	a	
subcutaneous injection or a nasal spray; the average dose admin‐
istered	was	not	specified.	Measured	outcomes	included	“complete	
response”	(no	vomiting	after	treatment),	“effective	response”	(vom‐
iting	 frequency	 reduced	 by	≥	50%),	 or	 “non‐effective	 response”	
(the	 treatment	was	 not	 effective	 in	 preventing	 vomiting).	 For	 the	
11	patients	receiving	subcutaneous	sumatriptan	injection,	4/11	had	
complete	resolution,	5/11	had	effective	response,	and	2/11	had	a	














associated	CVS	 had	 fewer	 emeses/episode,	more	 abdominal	 pain,	
and	more	 triggering	 events	 for	 their	CVS	episodes.	 Li	 et	al.	 found	
that	 24/35	 (69%)	 of	 children	 had	 improvement	 in	 symptoms	 (de‐
fined	as	a	≥	50%	reduction	in	vomiting	episodes)	with	subcutaneous	
sumatriptan.
Indirect	 estimates	 for	 the	 effect	 of	 sumatriptan	 on	 symptom	
reduction	 (nausea	 and	 vomiting)	 were	 derived	 from	 the	 migraine	
headache literature.22	 In	 a	 systematic	 review	of	 patients	with	mi‐
graine	headaches,	but	not	necessarily	CVS,	of	8	randomized	control	
trials,	 45%	 to	 76%	of	 individuals	with	migraine	 headaches	 experi‐
enced a reduction in nausea symptoms within 2 hours with triptans 
and	higher	rates	of	symptom	improvement	were	seen	in	individuals	
receiving sumatriptan by either intranasal (50%‐60% range) and sub‐
cutaneous routes (76%).22
Among	the	3	studies	that	included	data	on	the	use	of	triptans	
as	 abortive	 therapy	 in	 CVS,	 no	 adverse	 events	 were	 reported.	
12,23	Furthermore,	no	data	on	adverse	events	leading	to	treatment	
discontinuation	were	 provided	 in	 the	Derry	 et	al.	 Cochrane	 sys‐
tematic	review.	Adverse	effects	were	generally	described	as	mild	
or	 moderate	 and	 self‐limited.	 No	 cardiovascular	 problems	 were	
noted.
Certainty in the evidence
Indirect	estimates	influenced	the	certainty	of	the	evidence	supporting	
the	utility	of	triptans	as	abortive	therapy	in	CVS.	With	regard	to	the	





migraine and its equivalents).
With	 regard	 to	 the	 outcome	 of	 treatment	 response	 and	 ad‐
verse	 events	 (across	 the	 three	 studies	 in	 CVS	 patients),	 the	
certainty	in	the	evidence	was	deemed	to	be	very	low.	We	down‐





3.3.2 | Should 5‐HT3 antagonists be used as 
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3.3.3 | Should aprepitant be used as 
abortive therapy in adults with CVS?
Key message
In	patients	with	CVS,	there	is	very	low	certainty	in	the	evidence	for	
the	use	of	aprepitant	as	abortive	 therapy.	See	Table	9	 for	 full	evi‐
dence	profile
Potential benefits/harms
One	observational	 study	 investigated	 the	use	of	aprepitant	as	abor‐
tive therapy and	as	prophylactic	therapy	in	CVS.16 The study included 
pediatric	 patients	 and	 was	 retrospective	 in	 design,	 collecting	 data	
from	administrative,	pharmacy,	 and	clinical	databases	 as	well	 as	 tel‐






received the medication in the abortive group. There were no noted 
adverse	events	from	aprepitant	administration	in	the	abortive	group.
Certainty in the evidence
The	 certainty	 in	 the	 evidence	 was	 deemed	 to	 be	 very	 low,	 for	
the	same	reasons	discussed	 in	the	prophylactic	group.	Certainty	
was	 reduced	by	 risk	of	 bias	 (lack	of	 a	 control	 population,	 possi‐
ble	selection	bias,	and	confounding).	There	was	also	concern	re‐
garding	 indirectness,	given	 that	 the	study	 included	a	population	
that	failed	prior	CVS	treatments,	and	was	on	several	concomitant	
medications.
3.3.4 | Should we screen for and treat co‐
morbid conditions, such as anxiety, depression, 
migraine headache, autonomic dysfunction, sleep 
disorders, and substance use in adults with CVS?
No	published	studies	were	found	that	explicitly	addressed	this	ques‐
tion.	No	GRADE	evidence	profile	was	created.
3.3.5 | Should meditation, relaxation, and 




3.3.6 | Areas of limited/insufficient evidence
Three	 recommendations	 (recommendations	 7,	 9,	 and	 10)	 that	
are presented in the accompanying manuscript were deemed 
consensus	 recommendations	 and	 no	 GRADE	 evidence	 profile	
was	 created.	 Recommendation	 7	 addresses	 the	 role	 of	 5‐HT3	





(PONV)	 in	 treating	 acute,	 delayed,	 and	 anticipatory	 nausea	 and	
vomiting	to	inform	the	recommendation.	For	recommendations	9	










evidenced‐based psychotherapy to address psychiatric co‐mor‐
bidity.	 Finally,	 the	 guideline	 also	 includes	 consensus	 statements	
that	 address	 the	 diagnosis	 and	workup	 of	 CVS	 patients	 as	 well	
as	a	narrative	 review	and	sample	protocol	 for	 treatment	of	CVS	
patients	in	the	ED.
4  | CONCLUSIONS
This	 evidence	 review	 is	 based	 on	 the	GRADE	 framework	 and	was	
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